WuXi Biologics (Cayman) Stock | 2269.HK | KYG970081173 | A2QJCN | June 2025

Date	WuXi Biologics (Cayman) Price
6/16/2025	0 undefined
6/16/2025	24.29 undefined
6/13/2025	25.53 undefined
6/12/2025	25.48 undefined
6/11/2025	24.36 undefined
6/10/2025	24.28 undefined
6/9/2025	23.82 undefined
6/6/2025	22.64 undefined
6/5/2025	22.81 undefined
6/4/2025	23.09 undefined
6/3/2025	22.58 undefined
6/2/2025	22.91 undefined
5/30/2025	22.82 undefined
5/29/2025	23.64 undefined
5/28/2025	21.39 undefined
5/27/2025	21.76 undefined
5/26/2025	21.19 undefined
5/23/2025	21.87 undefined
5/22/2025	22.14 undefined
5/21/2025	22.72 undefined
5/20/2025	22.27 undefined
5/19/2025	21.90 undefined

Date	WuXi Biologics (Cayman) Revenue	WuXi Biologics (Cayman) EBIT	WuXi Biologics (Cayman) Net Income
2030e	40.74 B undefined	0 undefined	7.98 B undefined
2029e	36.52 B undefined	9.56 B undefined	6.83 B undefined
2028e	31.47 B undefined	8.56 B undefined	6.34 B undefined
2027e	28.77 B undefined	8.21 B undefined	6.33 B undefined
2026e	24.89 B undefined	6.92 B undefined	5.35 B undefined
2025e	21.6 B undefined	5.83 B undefined	4.52 B undefined
2024	18.68 B undefined	4.83 B undefined	3.36 B undefined
2023	17.03 B undefined	4.15 B undefined	3.4 B undefined
2022	15.27 B undefined	4.56 B undefined	4.42 B undefined
2021	10.29 B undefined	3.31 B undefined	3.39 B undefined
2020	5.61 B undefined	1.64 B undefined	1.69 B undefined
2019	3.98 B undefined	1.06 B undefined	1.01 B undefined
2018	2.53 B undefined	696.82 M undefined	630.59 M undefined
2017	1.62 B undefined	438.92 M undefined	252.63 M undefined
2016	989.03 M undefined	230.05 M undefined	141.1 M undefined
2015	557.04 M undefined	61.4 M undefined	44.51 M undefined
2014	331.85 M undefined	51.57 M undefined	41.98 M undefined

	Revenue	EBIT	Net Income
2014	331.85 M CNY	51.57 M CNY	41.98 M CNY
2015	557.04 M CNY	61.4 M CNY	44.51 M CNY
2016	989.03 M CNY	230.05 M CNY	141.1 M CNY
2017	1.62 B CNY	438.92 M CNY	252.63 M CNY
2018	2.53 B CNY	696.82 M CNY	630.59 M CNY
2019	3.98 B CNY	1.06 B CNY	1.01 B CNY
2020	5.61 B CNY	1.64 B CNY	1.69 B CNY
2021	10.29 B CNY	3.31 B CNY	3.39 B CNY
2022	15.27 B CNY	4.56 B CNY	4.42 B CNY
2023	17.03 B CNY	4.15 B CNY	3.4 B CNY
2024	18.68 B CNY	4.83 B CNY	3.36 B CNY
2025e	21.6 B CNY	5.83 B CNY	4.52 B CNY
2026e	24.89 B CNY	6.92 B CNY	5.35 B CNY
2027e	28.77 B CNY	8.21 B CNY	6.33 B CNY
2028e	31.47 B CNY	8.56 B CNY	6.34 B CNY
2029e	36.52 B CNY	9.56 B CNY	6.83 B CNY
2030e	40.74 B CNY	0 CNY	7.98 B CNY

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0.33	0.56	0.99	1.62	2.53	3.98	5.61	10.29	15.27	17.03	18.68	21.6	24.89	28.77	31.47	36.52	40.74
-	68.28	77.56	63.60	56.61	57.18	40.90	83.36	48.38	11.57	9.63	15.64	15.27	15.58	9.38	16.03	11.56
37.16	32.32	39.33	40.79	40.13	41.63	45.12	46.92	44.04	40.08	40.96	35.42	30.73	26.59	24.31	20.95	18.78
0.12	0.18	0.39	0.66	1.02	1.66	2.53	4.83	6.72	6.83	7.65	0	0	0	0	0	0
0.04	0.04	0.14	0.25	0.63	1.01	1.69	3.39	4.42	3.4	3.36	4.52	5.35	6.33	6.34	6.83	7.98
-	7.32	220.45	78.72	150.00	60.79	66.63	100.71	30.46	-23.10	-1.27	34.54	18.54	18.35	0.03	7.77	16.87
0.96	2.89	2.89	3.48	3.94	4	4.21	4.42	4.38	4.35	4.23	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.01	0.16	0.17	2.06	4.08	6.75	8.48	11.13	8.71	11.24	10.71
0.13	0.19	0.29	0.31	0.8	1.37	2.36	3.26	5.14	6.15	5.71
0.03	0.09	0.13	0.3	0.3	0.4	0.76	1.59	0.98	0.63	0.7
0.06	0.15	0.2	0.34	0.23	0.4	1.08	1.69	2.28	1.77	1.52
0	0.01	0.04	0.02	0.33	0.75	1.52	1.86	1.35	1.41	4.93
0.23	0.6	0.83	3.03	5.75	9.67	14.2	19.53	18.47	21.2	23.57
0.4	0.75	1.15	1.78	2.9	6.8	12.87	19.76	25.92	29.94	28.44
0	0	0	0.02	0.19	0.45	1.07	2.2	2.71	2.93	2.4
0	0	0	0	0	0	87.67	124.49	109.17	165.5	85.67
0	0	0	0	331.81	415.85	391.86	600.65	548.78	511.83	442.37
0	0	0	0	0	0.19	0.19	1.53	1.53	1.53	1.53
2.67	1.61	2.37	18.23	219.97	80.61	150.48	289.21	281.45	296.47	511.1
0.41	0.76	1.16	1.82	3.65	7.93	14.76	24.5	31.09	35.38	33.4
0.64	1.36	1.98	4.85	9.39	17.6	28.96	44.03	49.56	56.58	56.98

0	0	158	192	202	214	225	235	233	235	226
0	0	0	3.44	6.65	10.26	15.95	27.04	22.1	24.49	23.53
0.37	0.15	0.27	0.59	1.33	2.51	4.41	8.23	13.58	17.61	19.97
0	0	0	0	11.8	12.59	211.98	-449.33	-547.49	-735.42	-1,545.36
0	0	0	0	0	0	-2.69	-32.51	-92.24	-113.04	-134.53
0.37	0.15	0.27	4.02	7.99	12.78	20.56	34.8	35.05	41.25	41.82
0.15	0.27	0.11	0.14	0.22	0.19	0.65	0.62	0.79	3.59	3.53
4.28	37.27	56.34	85.24	142.16	257.04	500.99	830.05	970.36	793.33	825.39
0.05	0.44	0.41	0.58	0.96	1.9	2.52	4.58	6.08	5.28	4.43
0.05	0.46	0.18	0	0	0.51	0.77	2.12	0	0	0
0	0	0.05	0	0	0.03	0.06	0.1	1.47	0.73	2.62
0.26	1.2	0.8	0.8	1.32	2.87	4.5	8.26	9.32	10.39	11.4
0	0	0.9	0	0	1.66	2.5	2.07	2.95	3.83	2.32
0	0	5.49	6.82	2.68	24.73	180.89	124.21	132.08	122.54	97.31
3.95	8.79	12.56	19.71	77.49	148.89	880.95	876.73	949.46	969.23	460.47
0	0.01	0.91	0.03	0.08	1.83	3.57	3.07	4.03	4.92	2.88
0.26	1.21	1.71	0.82	1.4	4.71	8.06	11.33	13.35	15.31	14.28
0.63	1.36	1.98	4.85	9.39	17.49	28.63	46.12	48.4	56.56	56.1

2014	2015	2016	2017	2018	2019	2020	2021	2022
0.05	0.07	0.18	0.3	0.74	1.13	1.97	3.99	5.36
42	57	93	87	141	221	303	481	800
0	0	0	0	0	0	0	0	0
-77	-43	-253	-157	-297	-294	-461	-1,313	-1,560
7	28	66	126	180	154	73	269	943
2	2	30	36	0	49	82	83	108
2	3	47	43	52	78	94	349	585
0.02	0.11	0.08	0.36	0.76	1.21	1.88	3.43	5.54
-51	-334	-428	-670	-1,673	-3,234	-6,024	-6,523	-5,868
-50	-336	-421	-2,213	-416	-4,493	-7,216	-9,601	-5,908
0	-0	0.01	-1.54	1.26	-1.26	-1.19	-3.08	-0.04
0	0	0	0	0	0	0	0	0
0	-0	0.89	-0.9	0	1.89	0.82	-0.15	-0.3
0	0	0	3.57	3.21	3.53	5.58	8.46	-2.8
0.03	0.38	0.33	2.23	3.21	5.41	6.57	8.21	-2.59
30	381	-560	-440	0	-8	159	-104	507
0	0	0	0	0	0	0	0	0
0	0.15	0.01	0.33	3.58	2.12	0.89	1.91	-2.61
-29.54	-227.21	-346.96	-310.32	-912.23	-2,026.58	-4,143.5	-3,091.86	-326.72
0	0	0	0	0	0	0	0	0

WuXi Biologics (Cayman) Gross margin	WuXi Biologics (Cayman) Profit margin	WuXi Biologics (Cayman) EBIT margin	WuXi Biologics (Cayman) Profit margin
2030e	40.97 %	0 %	19.59 %
2029e	40.97 %	26.18 %	18.7 %
2028e	40.97 %	27.21 %	20.14 %
2027e	40.97 %	28.54 %	22.02 %
2026e	40.97 %	27.8 %	21.5 %
2025e	40.97 %	27.02 %	20.91 %
2024	40.97 %	25.86 %	17.97 %
2023	40.08 %	24.35 %	19.96 %
2022	44.04 %	29.85 %	28.95 %
2021	46.93 %	32.16 %	32.93 %
2020	45.13 %	29.31 %	30.09 %
2019	41.64 %	26.66 %	25.45 %
2018	40.16 %	27.49 %	24.88 %
2017	40.8 %	27.11 %	15.61 %
2016	39.34 %	23.26 %	14.27 %
2015	32.44 %	11.02 %	7.99 %
2014	37.14 %	15.54 %	12.65 %

	Gross margin	EBIT margin	Profit margin
2014	37.14 %	15.54 %	12.65 %
2015	32.44 %	11.02 %	7.99 %
2016	39.34 %	23.26 %	14.27 %
2017	40.8 %	27.11 %	15.61 %
2018	40.16 %	27.49 %	24.88 %
2019	41.64 %	26.66 %	25.45 %
2020	45.13 %	29.31 %	30.09 %
2021	46.93 %	32.16 %	32.93 %
2022	44.04 %	29.85 %	28.95 %
2023	40.08 %	24.35 %	19.96 %
2024	40.97 %	25.86 %	17.97 %
2025e	40.97 %	27.02 %	20.91 %
2026e	40.97 %	27.8 %	21.5 %
2027e	40.97 %	28.54 %	22.02 %
2028e	40.97 %	27.21 %	20.14 %
2029e	40.97 %	26.18 %	18.7 %
2030e	40.97 %	0 %	19.59 %

Date	WuXi Biologics (Cayman) Sales per Share	WuXi Biologics (Cayman) EBIT per share	WuXi Biologics (Cayman) Earnings per Share
2030e	9.64 undefined	0 undefined	1.89 undefined
2029e	8.64 undefined	0 undefined	1.62 undefined
2028e	7.44 undefined	0 undefined	1.5 undefined
2027e	6.81 undefined	0 undefined	1.5 undefined
2026e	5.89 undefined	0 undefined	1.27 undefined
2025e	5.11 undefined	0 undefined	1.07 undefined
2024	4.42 undefined	1.14 undefined	0.79 undefined
2023	3.92 undefined	0.95 undefined	0.78 undefined
2022	3.49 undefined	1.04 undefined	1.01 undefined
2021	2.33 undefined	0.75 undefined	0.77 undefined
2020	1.33 undefined	0.39 undefined	0.4 undefined
2019	1 undefined	0.27 undefined	0.25 undefined
2018	0.64 undefined	0.18 undefined	0.16 undefined
2017	0.47 undefined	0.13 undefined	0.07 undefined
2016	0.34 undefined	0.08 undefined	0.05 undefined
2015	0.19 undefined	0.02 undefined	0.02 undefined
2014	0.34 undefined	0.05 undefined	0.04 undefined

	Sales per Share	EBIT per share	Earnings per Share
2014	0.34 CNY	0.05 CNY	0.04 CNY
2015	0.19 CNY	0.02 CNY	0.02 CNY
2016	0.34 CNY	0.08 CNY	0.05 CNY
2017	0.47 CNY	0.13 CNY	0.07 CNY
2018	0.64 CNY	0.18 CNY	0.16 CNY
2019	1 CNY	0.27 CNY	0.25 CNY
2020	1.33 CNY	0.39 CNY	0.4 CNY
2021	2.33 CNY	0.75 CNY	0.77 CNY
2022	3.49 CNY	1.04 CNY	1.01 CNY
2023	3.92 CNY	0.95 CNY	0.78 CNY
2024	4.42 CNY	1.14 CNY	0.79 CNY
2025e	5.11 CNY	0 CNY	1.07 CNY
2026e	5.89 CNY	0 CNY	1.27 CNY
2027e	6.81 CNY	0 CNY	1.5 CNY
2028e	7.44 CNY	0 CNY	1.5 CNY
2029e	8.64 CNY	0 CNY	1.62 CNY
2030e	9.64 CNY	0 CNY	1.89 CNY

	Number of stocks
2014	964 M Aktien
2015	2.89 B Aktien
2016	2.89 B Aktien
2017	3.48 B Aktien
2018	3.94 B Aktien
2019	4 B Aktien
2020	4.21 B Aktien
2021	4.42 B Aktien
2022	4.38 B Aktien
2023	4.35 B Aktien
2024	4.23 B Aktien
2025e	4.23 B Aktien
2026e	4.23 B Aktien
2027e	4.23 B Aktien
2028e	4.23 B Aktien
2029e	4.23 B Aktien
2030e	4.23 B Aktien

Date	EPS Estimate	EPS Actual	Quarterly report
12/31/2021	0.36	0.35 (-1.96 %)	2021 Q4
6/30/2021	0.42	0.4 (-4.35 %)	2021 Q2

%	Name	Stocks	Change	Date
13.81993 %	WuXi Biologics Holdings Limited	584,191,133	0	6/24/2024
2.65805 %	The Vanguard Group, Inc.	112,360,289	164,000	1/31/2025
2.39385 %	BlackRock Institutional Trust Company, N.A.	101,191,969	-2,316,000	8/8/2024
1.84724 %	Norges Bank Investment Management (NBIM)	78,085,783	10,518,199	12/31/2024
1.65948 %	Schroder Investment Management North America Inc.	70,149,000	0	12/31/2024
1.45647 %	Bosera Asset Management Co., Ltd.	61,567,500	23,077,500	6/30/2024
1.32290 %	GF Fund Management Co., Ltd.	55,921,000	23,267,500	6/30/2024
1.31197 %	Hang Seng Investment Management Ltd.	55,458,922	1,430,808	1/31/2025
1.30900 %	Schroder Investment Management (Hong Kong) Ltd.	55,333,500	13,660,500	12/31/2024
1.05048 %	Dimensional Fund Advisors, L.P.	44,405,500	6,852,500	1/31/2025
1.01448 %	State Street Global Advisors Asia Ltd.	42,883,950	168,021	10/31/2023
1.00022 %	BlackRock Asset Management Ireland Limited	42,280,877	-7,414,992	8/8/2024
0.97365 %	BlackRock Advisors (UK) Limited	41,157,865	-116,500	1/31/2025
0.73557 %	JP Morgan Asset Management	31,093,818	2,538,669	5/16/2024
0.72725 %	China Merchants Fund Management Co. Ltd.	30,742,086	23,280,814	6/30/2024
0.67129 %	China Asset Management Co., Ltd.	28,376,500	0	9/30/2024
0.66631 %	Nuveen LLC	28,166,135	7,764	1/31/2025
0.59030 %	Harvest Fund Management Co., Ltd.	24,953,000	-5,490,500	6/30/2024
0.52051 %	Invesco Advisers, Inc.	22,003,000	21,746,000	12/31/2024
0.51715 %	Hongde Fund Management Co., Ltd.	21,860,649	10,859,500	6/30/2024
0.50873 %	JPMorgan Asset Management (Asia Pacific) Limited	21,505,000	-174,639	5/16/2024
0.49483 %	Zhong Ou Asset Management Co., Ltd.	20,917,169	-10,948,000	6/30/2024
0.41589 %	Geode Capital Management, L.L.C.	17,580,506	8,500	1/31/2025
0.39702 %	China Asset Management (Hong Kong) Limited	16,782,594	695,319	9/30/2024
0.33566 %	Chen (Zhisheng)	14,189,015	-61,499	11/20/2024
0.30992 %	APG Asset Management N.V.	13,100,944	1,680,143	12/31/2023
0.29764 %	INVESCO Great Wall Fund Management Co. Ltd.	12,581,918	-12,240,500	6/30/2024
0.27172 %	BlackRock Investment Management (UK) Ltd.	11,486,195	7,710,195	8/7/2024
0.26686 %	Penghua Fund Management Co., Ltd.	11,280,685	2,684,500	6/30/2024
0.26390 %	UBS Asset Management (Hong Kong) Limited	11,155,500	-44,000	9/30/2024
0.26056 %	E Fund Management Co. Ltd.	11,014,500	-123,661,500	6/30/2024
0.23032 %	China Southern Asset Management Co. Ltd.	9,736,000	6,181,800	6/30/2024
0.22945 %	HSBC JinTrust Fund Management Co., Ltd.	9,699,037	4,458,532	6/30/2024
0.22774 %	HuaAn Fund Management Co., Ltd.	9,627,000	3,674,000	6/30/2024
0.22006 %	ICBC Credit Suisse Asset Management Co. Ltd.	9,302,165	-468,835	6/30/2024
0.20749 %	Templeton Asset Management Ltd.	8,770,845	21,000	1/31/2025
0.20608 %	Li (Ge)	8,711,500	2,645,000	6/24/2024
0.19226 %	Amundi Asset Management, SAS	8,127,000	-22,500	1/31/2025
0.18611 %	State Street Global Advisors (US)	7,867,226	-12,500	1/31/2025
0.18384 %	Franklin Templeton International Services SARL	7,771,267	0	12/31/2024
0.17751 %	UBS Asset Management (UK) Ltd.	7,503,810	45,500	1/31/2025
0.17095 %	Baillie Gifford & Co.	7,226,500	-48,500	12/31/2024
0.17026 %	Allianz Global Investors Asia Pacific Limited	7,197,000	0	12/31/2024
0.16970 %	Chautauqua Capital Management, LLC	7,173,662	209,733	12/31/2024
0.16962 %	BlackRock (Netherlands) B.V.	7,170,182	7,170,182	8/8/2024
0.16406 %	State Street Global Advisors (UK) Ltd.	6,935,190	-1,435	1/31/2025
0.16107 %	California Public Employees' Retirement System	6,808,811	-379,000	6/30/2023
0.14635 %	Royal London Asset Management Ltd.	6,186,500	-224,500	11/30/2024
0.14577 %	Huashang Fund Management Co., Ltd.	6,162,130	2,432,130	6/30/2024
0.14378 %	Aviva Investors Global Services Limited	6,077,879	32,001	12/31/2024
0.14375 %	Northern Trust Global Investments Limited	6,076,500	309,000	12/31/2024
0.13416 %	Baring Asset Management Ltd.	5,671,214	0	1/31/2025
0.13368 %	Barings (U.K.) Limited	5,651,000	0	11/30/2024
0.13167 %	Goldman Sachs Asset Management, L.P.	5,566,102	-5,991	12/31/2024
0.12987 %	HSBC Global Asset Management (UK) Limited	5,489,657	151,333	12/31/2024
0.12918 %	BlackRock (Singapore) Limited	5,460,467	62,910	1/31/2025
0.12895 %	PGGM Vermogensbeheer B.V.	5,451,013	2,637,716	7/31/2024
0.12731 %	Dimensional Fund Advisors, Ltd.	5,381,500	0	12/31/2024
0.12347 %	Bank of Communications Schroder Fund Management Co., Ltd.	5,219,328	-19,014,877	6/30/2024
0.11580 %	UBS Fund Management (Switzerland) AG	4,895,000	-79,500	1/31/2025
0.11434 %	Mediolanum International Funds Limited	4,833,500	2,008,500	9/30/2024
0.11100 %	Sands Capital Management, LLC	4,692,130	-6,137,010	3/31/2024
0.11093 %	Capital Research Global Investors	4,689,000	-37,500	12/31/2024
0.10191 %	Franklin Templeton Investment Management Ltd.	4,307,937	0	10/31/2024
0.10120 %	China Universal Asset Management Co., Ltd.	4,278,000	-9,283,700	6/30/2024
0.10042 %	DWS Investment GmbH	4,244,915	3,574	1/31/2025
0.09892 %	Charles Schwab Investment Management, Inc.	4,181,430	0	1/31/2025
0.09328 %	Fullgoal Fund Management Co., Ltd.	3,943,023	1,702,450	6/30/2024
0.08991 %	Mirae Asset Global Investments (Hong Kong) Limited	3,800,495	0	9/30/2024
0.08694 %	Amundi Japan Ltd.	3,675,000	76,500	1/31/2025
0.08668 %	Essence Fund Management Co., Ltd.	3,664,000	1,512,000	6/30/2024
0.08528 %	AEGON Investment Management B.V.	3,605,085	-8,317	10/31/2024
0.07724 %	First Sentier Investments (U.K.) Ltd	3,265,000	0	12/31/2024
0.07557 %	Huatai-PineBridge Fund Management Co., Ltd.	3,194,413	-3,699,190	6/30/2024
0.07350 %	UBS Asset Management (Switzerland)	3,107,000	0	1/31/2025
0.07269 %	Edmond de Rothschild Asset Management (France) S.A.	3,072,636	70,089	11/30/2024
0.07154 %	DWS Investments UK Limited	3,024,210	0	1/31/2025
0.06522 %	Pictet Asset Management Ltd.	2,757,068	0	12/31/2024
0.06356 %	Legal & General Investment Management Ltd.	2,686,841	0	1/31/2025
0.06005 %	ZhongGeng Fund Management Co., Ltd.	2,538,500	2,538,500	6/30/2024
0.05914 %	Franklin Templeton Sealand Fund Management Co., Ltd.	2,500,000	2,500,000	6/30/2024
0.05678 %	S-Bank Fund Management Ltd	2,400,000	0	7/31/2024
0.05465 %	An Zhong (AZ) Investment Management Hong Kong Ltd.	2,310,000	0	9/30/2024
0.05274 %	Florida State Board of Administration	2,229,500	-745,000	6/30/2024
0.05219 %	BOCI-Prudential Asset Management Ltd.	2,206,247	2,000	7/31/2024
0.05177 %	Yinhua Fund Management Co., Ltd.	2,188,500	1,037,000	6/30/2024
0.04882 %	Handelsbanken Kapitalförvaltning AB	2,063,500	-81,000	1/31/2025
0.04787 %	Tianhong Asset Management Co., Ltd.	2,023,716	30,003	6/30/2024
0.04750 %	Allspring Global Investments, LLC	2,008,000	0	12/31/2024
0.04576 %	California State Teachers Retirement System	1,934,338	-1,809,500	6/30/2024
0.04459 %	Bellevue Asset Management AG	1,885,000	150,000	12/31/2024
0.04440 %	Mellon Investments Corporation	1,876,900	-19,500	1/31/2025
0.04435 %	Guotai Asset Management Co., Ltd.	1,874,548	597,157	6/30/2024
0.04388 %	CSOP Asset Management Limited	1,854,847	-28,000	1/31/2025
0.04271 %	Zürcher Kantonalbank (Asset Management)	1,805,347	0	12/31/2024
0.04058 %	Franklin Advisers, Inc.	1,715,500	315,000	1/31/2025
0.03944 %	BlackRock Asset Management North Asia Limited	1,667,402	620,248	12/31/2024
0.03627 %	Mercer Global Investments Management Ltd	1,533,000	-867,500	12/31/2024
0.03272 %	HFT Investment Management Co., Ltd.	1,383,000	130,500	6/30/2024
0.03268 %	Schroder Investment Management Ltd. (SIM)	1,381,438	0	11/30/2024

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Amicus Therapeutics	SupplierCustomer	0,87	0,16	0,22	0,70	0,57	-0,19
ABL Bio	SupplierCustomer	0,80	0,69	0,39	0,04	-0,65	-0,76
Sino Biopharmaceutical	SupplierCustomer	0,80	0,47	0,69	0,78	0,87	-0,04
Legochem Biosciences	SupplierCustomer	0,73	0,82	0,23	0,60	0,65	0,10
AC Immune	SupplierCustomer	0,68	0,77	0,42	0,79	0,92	0,49
Oncorus	SupplierCustomer	0,67	0,35	0,46	0,91	0,92
Antengene Corp Rg	SupplierCustomer	0,65	0,09	0,54	0,90	0,92
Cullinan Oncology	SupplierCustomer	0,65	0,49	0,23	0,72	0,91
Vir Biotechnology	SupplierCustomer	0,60	0,08	-0,02	0,86	0,77	0,41
Citigroup	SupplierCustomer	0,44	0,25	0,35	0,59	0,80	0,76

What values and corporate philosophy does WuXi Biologics (Cayman) represent?

WuXi Biologics (Cayman) Inc represents a strong set of values and a clear corporate philosophy. The company is committed to enabling global partners to develop and manufacture biologics efficiently and cost-effectively. WuXi Biologics is driven by a customer-centric approach, providing integrated solutions and the highest quality services to meet the diverse needs of its clients. With a focus on innovation, WuXi Biologics embraces cutting-edge technologies and invests in state-of-the-art facilities to ensure world-class bio-manufacturing capabilities. This dedication to excellence, along with a commitment to collaboration and integrity, positions WuXi Biologics as a trusted and leading player in the biopharmaceutical industry.

In which countries and regions is WuXi Biologics (Cayman) primarily present?

WuXi Biologics (Cayman) Inc is primarily present in China, with its headquarters in Shanghai. However, the company also has a global presence, with operations and facilities in multiple countries and regions. These include the United States, Germany, Ireland, Singapore, and China's Suzhou, Wuxi, and Hangzhou cities. With its international reach, WuXi Biologics (Cayman) Inc is well-positioned to cater to the global demand for biologics development, manufacturing, and supply chain solutions.

What significant milestones has the company WuXi Biologics (Cayman) achieved?

WuXi Biologics (Cayman) Inc, a leading global open-access biologics technology platform company, has achieved significant milestones since its inception. The company has rapidly expanded its capabilities and established strategic partnerships with global pharmaceutical giants. WuXi Biologics has successfully developed and launched numerous innovative biologics products, providing customized and high-quality solutions to its clients. Moreover, the company has received numerous accolades and recognition for its outstanding performance and contributions to the biopharmaceutical industry. Through its dedication to innovation and commitment to excellence, WuXi Biologics (Cayman) Inc continues to revolutionize the biologics landscape and drive advancements in healthcare.

What is the history and background of the company WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc, founded in 2011, is a leading global open-access Biologics technology platform company. It offers end-to-end solutions for biologics discovery, development, and manufacturing to support worldwide partners in advancing biologics through various stages of development. With state-of-the-art facilities and a team of experienced professionals, WuXi Biologics leverages its expertise in cell line development, process development, and biologics manufacturing to offer cost-effective and high-quality services. The company's commitment to innovation, quality, and customer satisfaction has propelled its rapid growth and success in the biopharmaceutical industry. WuXi Biologics (Cayman) Inc is dedicated to enabling global healthcare by providing access to biologics for patients worldwide.

Who are the main competitors of WuXi Biologics (Cayman) in the market?

The main competitors of WuXi Biologics (Cayman) Inc in the market include companies such as Lonza Group Ltd., Catalent Inc., and Samsung Biologics Co., Ltd.

In which industries is WuXi Biologics (Cayman) primarily active?

WuXi Biologics (Cayman) Inc primarily operates in the biopharmaceutical industry.

What is the business model of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc. operates as a global open-access biologics technology platform company. It provides a comprehensive range of services in discovery, development, and manufacturing of biologics. The company's business model focuses on offering end-to-end solutions to global pharmaceutical and biotech companies. WuXi Biologics offers integrated services encompassing cell line development, process development, analytical development, and biologics manufacturing, including clinical and commercial manufacturing. By providing high-quality and cost-effective solutions, WuXi Biologics has established itself as a leading player in the biologics industry, enabling its clients to accelerate their drug development programs and reduce manufacturing costs.

What is the P/E ratio of WuXi Biologics (Cayman) 2025?

The P/E ratio cannot be calculated for WuXi Biologics (Cayman) at the moment.

What is the P/S ratio of WuXi Biologics (Cayman) 2025?

The P/S cannot be calculated for WuXi Biologics (Cayman) currently.

What is the Quality Investing of WuXi Biologics (Cayman)?

The Quality Investing for WuXi Biologics (Cayman) is 8/10.

What is the revenue of WuXi Biologics (Cayman) 2025?

The expected WuXi Biologics (Cayman) revenue is 21.6 B CNY.

How high is the profit of WuXi Biologics (Cayman) 2025?

The expected WuXi Biologics (Cayman) profit is 4.52 B CNY.

What is the business model of WuXi Biologics (Cayman)

The company WuXi Biologics (Cayman) Inc is a worldwide leading provider of end-to-end solutions in the biopharmaceutical industry. The company specializes in the manufacturing of biological drugs and offers a wide range of services, from research and development to manufacturing and marketing of products. WuXi Biologics' business model is divided into three main areas: 1. Research and Development: The company offers a comprehensive range of services for biopharmaceutical research and development, including protein and antibody structure elucidation, biomarker identification, cell line development, and small molecule production. WuXi Biologics aims to support its customers in accelerating their research process, thereby shortening the timeframe for product availability in the market. 2. Manufacturing: WuXi Biologics is one of the world's largest providers of manufacturing services for biological drugs. The company has a broad range of technologies and capabilities to meet its customers' requirements, from non-clinical to commercial product manufacturing. WuXi Biologics' production facilities are certified by the FDA or EMA, and the company strives to meet the highest standards in production and compliance with quality controls. 3. Marketing and Distribution: WuXi Biologics also offers marketing and distribution services for biological drugs, including support in product launch and management of distribution networks. The company has an experienced team of industry analysts, market researchers, and sales experts who help customers maximize their market presence and increase profits. The products offered by WuXi Biologics include biologicals, small molecules, and sample preparation, such as antibodies, peptides, recombinant proteins, and oligonucleotides. The company also provides platform technologies such as CHO-S production, plasmid manufacturing, virus production, proteomic analysis, and clinical diagnostics. With its innovative technologies, wide range of services, and ability to collaborate with customers worldwide, WuXi Biologics has firmly established its reputation as a leading company in the biopharmaceutical industry.

What is the WuXi Biologics (Cayman) dividend?

WuXi Biologics (Cayman) pays a dividend of 0 CNY distributed over payouts per year.

How often does WuXi Biologics (Cayman) pay dividends?

The dividend cannot currently be calculated for WuXi Biologics (Cayman) or the company does not pay out a dividend.

What is the WuXi Biologics (Cayman) ISIN?

The ISIN of WuXi Biologics (Cayman) is KYG970081173.

What is the WuXi Biologics (Cayman) WKN?

The WKN of WuXi Biologics (Cayman) is A2QJCN.

What is the WuXi Biologics (Cayman) ticker?

The ticker of WuXi Biologics (Cayman) is 2269.HK.

How much dividend does WuXi Biologics (Cayman) pay?

Over the past 12 months, WuXi Biologics (Cayman) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WuXi Biologics (Cayman) is expected to pay a dividend of 0 CNY.

What is the dividend yield of WuXi Biologics (Cayman)?

The current dividend yield of WuXi Biologics (Cayman) is .

When does WuXi Biologics (Cayman) pay dividends?

WuXi Biologics (Cayman) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) paid dividends every year for the past 0 years.

What is the dividend of WuXi Biologics (Cayman)?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is WuXi Biologics (Cayman) located?

WuXi Biologics (Cayman) is assigned to the 'Health' sector.

Wann musste ich die Aktien von WuXi Biologics (Cayman) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WuXi Biologics (Cayman) from 6/17/2025 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2025.

When did WuXi Biologics (Cayman) pay the last dividend?

The last dividend was paid out on 6/17/2025.

What was the dividend of WuXi Biologics (Cayman) in the year 2024?

In the year 2024, WuXi Biologics (Cayman) distributed 0 CNY as dividends.

In which currency does WuXi Biologics (Cayman) pay out the dividend?

The dividends of WuXi Biologics (Cayman) are distributed in CNY.

Scope 1 - Direct Emissions	32,687
Scope 2 - Indirect emissions from purchased energy	149,229
Scope 3 - Indirect emissions within the value chain	65,463.77
Total CO₂ emissions	181,916
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees	53
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Stock Exchange	WuXi Biologics (Cayman) Ticker
DÜSSELDORF	1FW2.DU
FRANKFURT	1FW2.F
HKSE	2269.HK
MUNICH	1FW2.MU
PNK	WXIBF

WuXi Biologics (Cayman) Ticker	WuXi Biologics (Cayman) FIGI
2269:HK	BBG00GTY47H0
1FW2:GR	BBG00GXQDVD3
1FW2:GF	BBG00GXQDVF1
1FW2:GD	BBG00GXQDVG0
1FW2:GS	BBG00GXQDVJ7
1FW2:GM	BBG00GXQDVK5
1FW2:GB	BBG00GXQDVL4
22691EUR:EO	BBG00GXY9799
22691EUR:XH	BBG00GXY97D4
22691EUR:XF	BBG00GXY97G1
22691EUR:XE	BBG00GXY97J8
22691EUR:XJ	BBG00GXY97K6
22691EUR:XL	BBG00GXY97L5
22691EUR:XG	BBG00GXY97M4
22691EUR:XO	BBG00GXY97N3
22691EUR:XA	BBG00GXY97T7
22691EUR:E1	BBG00GXY97V4
22691EUR:XT	BBG00GXY97W3
22691EUR:XW	BBG00GXY97X2
22691EUR:XU	BBG00GXY97Y1
22691EUR:XV	BBG00GXY97Z0
22691EUR:EU	BBG00GXY9815
2269:H2	BBG00HMKDMC7
2269:H1	BBG00HMKF104
WXIBF:US	BBG00HW3DBG4
WXIBF:PQ	BBG00HW3DBV7
WXIBF:UV	BBG00HW3DBW6
22691EUR:XX	BBG00JN8MQX7
2269N:L3	BBG00JRFL1G2
2269N:B3	BBG00JRFRRW1
2269N:PO	BBG00JRFXBK2
22691HKD:EO	BBG00JRGLFK4
22691HKD:XH	BBG00JRGLFN1
22691HKD:XF	BBG00JRGLFQ8
22691HKD:XE	BBG00JRGLFS6
22691HKD:XJ	BBG00JRGLFT5
22691HKD:XL	BBG00JRGLFV2
22691HKD:XG	BBG00JRGLFW1
22691HKD:XO	BBG00JRGLFX0
22691HKD:XA	BBG00JRGLG22
22691HKD:E1	BBG00JRGLG31
22691HKD:XT	BBG00JRGLG40
22691HKD:XW	BBG00JRGLG59
22691HKD:XU	BBG00JRGLG68
22691HKD:XV	BBG00JRGLG77
22691HKD:XM	BBG00JRGLG86
22691HKD:XQ	BBG00JRGLGB2
22691HKD:XX	BBG00JRGLGC1
22691HKD:XZ	BBG00JRGLGD0
22691HKD:EU	BBG00JRGLGG7
1FW:TH	BBG00L2RGBR0
22691HKD:X2	BBG00Q6SHJ59
1FW2:GZ	BBG00SSL1SB6
22691EUR:EP	BBG00SSQ7DN9
22691EUR:EZ	BBG00SSQ7DQ6
1FW2:QT	BBG00WR8TN37
2963N:L1	BBG00YB09YT7
2269N:MM	BBG00YG35MP0
2269N:MF	BBG00YG35MQ9
2269N:MU	BBG00YG35MR8
22691USD:EO	BBG00Z6CPDN8
22691USD:XH	BBG00Z6CPDR4
22691USD:XF	BBG00Z6CPDT2
22691USD:XE	BBG00Z6CPDW8
22691USD:XJ	BBG00Z6CPDX7
22691USD:XL	BBG00Z6CPDY6
22691USD:XG	BBG00Z6CPDZ5
22691USD:XO	BBG00Z6CPF08
22691USD:XA	BBG00Z6CPF44
22691USD:XT	BBG00Z6CPF62
22691USD:XW	BBG00Z6CPF71
22691USD:XU	BBG00Z6CPF80
22691USD:XV	BBG00Z6CPFB6
22691USD:XM	BBG00Z6CPFC5
22691USD:EU	BBG00Z6CPFL5
1FW2:LA	BBG018H9J6S9
1FW2:LU	BBG018J357J3

Unlimited access to the most powerful analytical tools in finance.

Price

Price

Ticker2269.HK

ISINKYG970081173

WKNA2QJCN

WuXi Biologics (Cayman) stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

WuXi Biologics (Cayman) Stock Price History

WuXi Biologics (Cayman) Revenue, EBIT, Net Income KYG970081173 · A2QJCN

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

WuXi Biologics (Cayman) Revenue, EBIT and net profit per share

WuXi Biologics (Cayman) Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

WuXi Biologics (Cayman) stock margins KYG970081173 · A2QJCN

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

WuXi Biologics (Cayman) Margin History

WuXi Biologics (Cayman) Stock Sales Revenue, EBIT, Earnings per Share KYG970081173 · A2QJCN

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

WuXi Biologics (Cayman) Revenue, EBIT and net profit per share

WuXi Biologics (Cayman) business model

WuXi Biologics (Cayman) SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

WuXi Biologics (Cayman) Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

WuXi Biologics (Cayman) historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

WuXi Biologics (Cayman) shares outstanding KYG970081173 · A2QJCN

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

WuXi Biologics (Cayman) stock splits

The World’s Best Investors Are On Eulerpool

WuXi Biologics (Cayman) Earnings Estimates

WuXi Biologics (Cayman) latest earnings and earnings surprises

Eulerpool ESG Scorecard© for the WuXi Biologics (Cayman) stock

Eulerpool World ESG Rating (EESG©)

Ticker
2269.HK

ISIN
KYG970081173

WKN
A2QJCN